These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19555871)

  • 21. The renin-angiotensin-aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood pressure.
    Soldner A; Spahn-Langguth H; Mutschler E
    Pharmazie; 1996 Nov; 51(11):783-99. PubMed ID: 8985974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
    Mackay JA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 25. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).
    Lip GY; Beevers DG
    J Hum Hypertens; 2003 Nov; 17(11):747-50. PubMed ID: 14578913
    [No Abstract]   [Full Text] [Related]  

  • 27. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
    Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
    Pichler M; Klein W; Huber K; Pachinger O
    Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
    Nilsson PM; Cifkova R; Kjeldsen SE
    J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
    [No Abstract]   [Full Text] [Related]  

  • 36. Is there overlap in blood-pressure response to the blockers of the renin-angiotensin system between lower and higher renin subjects?
    Minami J; Ishimitsu T; Matsuoka H
    Am J Hypertens; 2008 Feb; 21(2):130-1; author reply 132. PubMed ID: 18268482
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood pressure in renal disease: how to accomplish the goal?
    Robles NR; Hernandez-Gallego R
    Cardiovasc Ther; 2012 Aug; 30(4):193-8. PubMed ID: 22759229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renin-angiotensin system and cardiovascular disease.
    Hollenberg NK
    Blood Press Suppl; 2000; 1():5-8. PubMed ID: 11059628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vaccine for hypertension.
    Ménard J
    J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
    [No Abstract]   [Full Text] [Related]  

  • 40. Blockage of the renin-angiotensin system in the secondary prevention of stroke: beneficial effects beyond blood pressure reduction?
    Castilla-Guerra L; del Carmen Fernández-Moreno M; Jiménez-Hernandez MD
    Stroke; 2009 Mar; 40(3):e75; author reply e76. PubMed ID: 19182077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.